Evidence map›Paper›PMID 30238377›Full record

ReviewTransgenic research2019

The Romanian experience and perspective on the commercial cultivation of genetically modified crops in Europe.

Mihael Cristin Ichim

Abstract readReview
PubMed Publisher
In one paragraph

Review in Transgenic research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. CRISPR/Cas9-Mediated Targeted Mutagenesis ofFrontiers in plant science · 2022
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mihael Cristin IchimNational Institute of Research and Development for Biological Sciences, "Stejarul" Research Centre for Biological Sciences, Alexandru cel Bun St., 6, 610004, Piatra Neamt, Romania. cichim@hotmail.com.ORCID http://orcid.org/0000-0002-8192-5544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Romania was the third country in Europe and the tenth in the world, to commercially adopt genetically modified crops in 1999, only 3 years after they were first marketed globally. Half a million hectares of transgenic herbicide resistant soybean and insect resistant maize were grown in Romania during an uninterrupted 17-year period. After several years of continued declining area, the commercial cultivation of transgenic plants recently ended. The commercial cultivation of transgenic crops in Romania remains legally and technically possible, according to the EU and national regulations. However, the declining area cultivated with these crops in Romania seems to be the result of farmers' conscious decision, while waiting for more profitable genetically modified crops to become available that better fit their needs. This expectation would be a logical result of the EU GMO opt-out Directive 2015/412 and the advent of the new plant breeding techniques. The GMO opt-out mechanism is still expected to unblock the EU authorization process after the large majority of the EU member states have already prohibited the cultivation of genetically modified organisms in their territory. As the new plant breeding techniques offer significant technical and economic advantages, they could be rapidly adopted by commercial breeders and farmers outside Europe. The Court of Justice of the European Union ruled that plants obtained with the new gene editing techniques must go through the same authorization procedure as transgenic plants. This decision is expected to delay the approval and availability of these new plant varieties on the EU market and their commercial cultivation.

Indexed as

Crops, AgriculturalFood, Genetically ModifiedAgricultureBiotechnologyEuropean UnionFood SafetyGlycine maxPlant BreedingPlants, Genetically ModifiedRomaniaZea maysEuropeGenome editingGM cropsGMOsNPBTsTransgenic plants

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.